Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes

References

• National diabetes statistics report: Estimates of diabetes and its burden in the United States, 2014. Centers for Disease Control and Prevention. Atlanta, GA: U.S. Department of Health and Human Services; 2014 [cited 2016 Jul 11]. Available from: https://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes - 2016. Diabetes Care. 2016;39(Suppl 1):S1–S112.
   Google Scholar
• Stark Casagrande S, Fradkin JE, Saydah SH, et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care. 2013;36(8):2271–2279.
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. NEJM. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• Kaufman F, editor. Medical management of type 1 diabetes. 6th ed. Alexandria, VA: American Diabetes Association; 2012.
   Google Scholar
• Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA. 2014;311(22):2315–2325.
   PubMed Web of Science ®Google Scholar
• Vora J, Cariou B, Evans M, et al. Clinical use of insulin degludec. Diabetes Res Clin Pr. 2015;109(1):19–31.
   PubMed Web of Science ®Google Scholar
• Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet. 2014;53(9):787–800.
   PubMed Web of Science ®Google Scholar
• Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: A pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15(2):175–184.
   PubMed Web of Science ®Google Scholar
• Becker RH, Dahmen R, Bergmann K, et al. New insulin glargine 300 units/ml provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units/ml. Diabetes Care. 2015;38(4):637–643.
   PubMed Web of Science ®Google Scholar
• Pettus J, Santos Cavaiola T, Tamborlane WV, et al. The past, present, and future of basal insulins. Diabetes Metab Res Rev. 2015. Published online 2015 Oct 28. DOI:10.1002/dmrr.2763
   PubMed Web of Science ®Google Scholar
• Toujeo (insulin glargine injection) U-300 prescribing information. Bridgewater, NJ: Sanofi-Aventis U.S., LLC; 2015 [cited 2016 Jul 11]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf
   Google Scholar
• Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab. 2015;17(3):254–260.
   PubMed Web of Science ®Google Scholar
• Becker RH, Nowotny I, Teichert L, et al. Low within- and between-day variability in exposure to new insulin glargine 300 U/ml. Diabetes Obes Metab. 2015;17(3):261–267.
   PubMed Web of Science ®Google Scholar
• Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014;16(9):873–876.
   PubMed Web of Science ®Google Scholar
• Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 1 diabetes: A randomized, phase 3a, open-label clinical trial (EDITION 4). Diabetes Care. 2015;38(12):2217–2225.
   PubMed Web of Science ®Google Scholar
• Matsuhisa M, Koyama M, Cheng X, et al. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP1). Diabetes Obes Metab. 2016;18(4):375–383.
   PubMed Web of Science ®Google Scholar
• Jinnouchi H, Koyama M, Amano A, et al. Continuous glucose monitoring during basal-bolus therapy using insulin glargine 300 U/ml and glargine 100 U/ml in Japanese people with type 1 diabetes mellitus: A crossover pilot study. Diabetes Ther. 2015;6(2):143–152.
   PubMed Web of Science ®Google Scholar
• Bergenstal R, Bailey TS, Rodbard D, et al. Insulin glargine 300 U/ml vs 100 U/ml: glucose profiles of morning vs evening injections in adults with T1DM measured with continuous glucose monitoring (CGM) [abstract]. Diabetes Technol Ther. 2015;17(S1):A16–17.
   Google Scholar
• Riddle MC, Bolli GB, Home PD, et al. Efficacy and safety of flexible versus fixed dosing intervals of insulin glargine 300 U/ml in people with type 2 diabetes. Diabetes Technol Ther. 2016;18(4):252–257.
   PubMed Web of Science ®Google Scholar
• Bolli GB, DeVries JH. New long-acting insulin analogs: from clamp studies to clinical practice. Diabetes Care. 2015;38(4):541–543.
   PubMed Web of Science ®Google Scholar
• Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–2762.
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 units/ml versus glargine 100 units/ml in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235–3243.
   PubMed Web of Science ®Google Scholar
• Bolli GB, Riddle MC, Bergenstal RM, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–394.
   PubMed Web of Science ®Google Scholar